Hikma Integrative Healthcare has unveiled EXOMIND, an FDA-cleared medical device offering a drug-free, non-invasive treatment for adults living with Major Depressive Disorder (MDD). Using Hikma’s patented ExoTMS technology, EXOMIND provides an innovative alternative for patients who have not responded to traditional antidepressant medications.
Health Technology Insights: Corus Orthodontists Secures C$20 Million Equity Investment
EXOMIND delivers targeted magnetic stimulation to critical brain regions involved in mood regulation, cognitive processing, and emotional control. This stimulation supports neuroplasticity and strengthens healthy neural pathways, helping to alleviate depressive symptoms while ensuring patient comfort throughout the sessions.
“This is a pivotal moment in mental health care,” said Dr. Aishah Suleiman of Hikma Integrative Healthcare. “Depression affects nearly one in five adults in the United States, and many have not found relief with medication. EXOMIND offers an accessible, evidence-based treatment that prioritizes comfort while delivering meaningful results.”
Health Technology Insights: AACN Teams with Xapify to Digitize Competence Framework
EXOMIND is an advanced form of Repetitive Transcranial Magnetic Stimulation, or rTMS, which has been used clinically to treat depression for over a decade. The ExoTMS system enhances patient comfort, and most individuals report the sensation as a light tapping on the scalp. In trials, over 90 percent of patients described the treatment as comfortable, with an average discomfort rating of just 0.2 on a 0 to 10 scale.
Clinical evidence further supports the therapy’s effectiveness. In a recent IRB-approved study, 83 percent of participants reported reduced depressive symptoms three months after completing EXOMIND treatment, while 88 percent showed improved overall mental wellbeing scores during the same follow-up period.
“At Hikma, we view mental wellness as essential to overall health, confidence, and quality of life,” Dr. Suleiman added. “EXOMIND represents a new approach to empowering patients to take control of their mental health without relying solely on medications. It is an exciting advancement that gives hope to those who need it most.”
EXOMIND therapy is currently available at Hikma Integrative Healthcare for adult patients diagnosed with MDD who meet treatment eligibility criteria.
Health Technology Insights: SEQSTER Expands Partnership with Praxis Precision Medicines
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
